I am writing to recommend the services of Algorithme Pharma. I have been using Algorithme Pharma services to conduct a Proof of Concept Phase I/Ila study in the therapeutic area of the Hepatic C Virus Infection starting in September 2013 and ending in January 2015.
They did an excellent job for this study: they were the 2nd better recruiter of HCV-infected subjects among 6 sites worldwide, always very transparent in their communication and with a focus on the quality.
As proofs of their performance:
- They completed the first part of the study in sequential dose escalation of Healthy Volunteers ( 48) and Genotype 1 HCV-infected subjects (15) in less than 3 months from regulatory submission to last subject dosed.
- They also successfully participated in the multiple dosing of several genotype HCV -infected subjects and delivered 6 subjects within 2 months in a highly competitive environment.
- A sponsor audit of their systems at the CRO offices and the Phase I Unit was conducted on June 2014 (4 days) and no major finding was found. Only 4 minor audit observations and one comment were raised which proves the high quality standards of Algorithme Pharma.
The team members from Algorithme Pharma were responsive, hard-working and client oriented. It was easy to work with them and they were always willing to take the time to discuss any concerns and respond to questions.
I feel confident in recommending Algorithme Pharma services.
If you need additional information please feel free to contact me.
Associate Director, Clinical Operations
Idenix, a wholly-owned subsidiary of Merck & Company